Quickly verify claims by accessing the underlying experimental data and figures.
Press Enter β΅ to solve
Fuel Your Discoveries
"The molecules of life are like letters of the alphabet. You can't tell what a word says by knowing the number of letters in it."
- Matt Ridley
Quick Explanation
Copied
BCYRN1 review (2021): what it claims
BCYRN1/BC200 is described as oncogenic in multiple cancers, typically upregulated in tumors and linked to worse prognosis.
Mechanisms are summarized as dominated by lncRNAβmiRNA interactions plus modulation of signaling axes including Notch, Wnt/Ξ²-catenin, PI3K/AKT, and Hippo.
Preclinical support in the review includes BCYRN1 silencing reducing tumor phenotypes in animal models; clinical targeting is stated to be untested at the time of writing.
Skeptical note: this is a narrative review with heterogeneous preclinical/correlational studies and it does not provide quantitative meta-analytic effect synthesis.
Epistemic framing: You provided the full text of the review article. What follows is a critical analysis of what this narrative review claims and what it does not, using only information explicitly present in the provided text. Where the review cites primary studies, I do not assume their methods or effect sizes beyond what the review itself states.
Main source used throughout:
1) Visual map of evidence types reported in the review
A compact schematic: what kind of evidence the review compiles (cell lines β animals β human cohorts) and the directionality of claims.
Interpretation is grounded in the reviewβs structure and statements; the review does not compute pooled effect sizes.
2) Quantitative visuals from the reviewβs own tables (sample sizes & diagnostic metrics)
The review includes explicit clinical sample counts in Table 3 and diagnostic performance numbers in Table 4. Below plots use only values stated in the provided text.
2A) Clinical sample counts by cancer type (from Table 3 excerpts in text)
Sample counts are taken directly from the table excerpts included in the provided text. The reviewβs tables may contain additional cohorts/cells not fully reproduced here, so the plot is strictly βwhat is visible in the provided excerpt.β
2B) Diagnostic performance reported in Table 4 (AUC, sensitivity, specificity)
Important skepticism: Table 4 mixes AUC (0β1) with sensitivity/specificity (%) in a single visualization. This is intentionally literal, but it also highlights a common interpretational pitfall: these are different scales. The review provides numeric values but does not describe cross-validation/independent external validation within the excerpt.
3) Mechanistic claims: what is consistent vs uncertain
The review repeatedly states that BCYRN1 acts through microRNA interactions and highlights repeated pathway themes. Below is a structured breakdown of what the review explicitly says.
Consistent: The review explicitly describes miRNA-centered mechanisms as βmost acknowledged,β naming multiple miRNA targets and downstream effects across cancers.
Consistent pathway themes: Notch, Wnt/Ξ²-catenin, PI3K/AKT, and Hippo are explicitly mentioned as signaling cascades impacted by BCYRN1.
Uncertainty / heterogeneity: The review notes contradictory findings in glioma across two cited studies (one reporting oncogenic phenotypes after BCYRN1 overexpression; another reporting suppressive effects depending on the miRNA axis).
Critical point: Because this is a narrative review, we cannot determine from the provided text whether the pathway statements reflect direct biochemical causality vs inferred correlations in the underlying studies.
4) What would falsify the reviewβs overarching claim?
Using the reviewβs own stated oncogenic narrative, the strictest falsification routes are direct effects on cellular/tumor phenotypes and consistent clinical directionality.
This falsification map is derived from the reviewβs narrative structure (expression β mechanism β phenotypes β clinical association/diagnostic performance). It does not add new evidence beyond what the provided text states.
5) Critical methodological appraisal (as a narrative review)
Primary limitation: narrative synthesis without quantitative meta-analysis. The review compiles many different studies across cancers, but the provided text does not indicate pooled effect sizes, standardized thresholds, or uniform risk-of-bias handling.
Heterogeneity problem: Multiple cancers and multiple mechanistic βroutesβ are discussed (miRNA axes + different signaling pathways). Without a consistent mechanistic throughline or standardized experimental endpoints, the βoncogenicβ label may partially reflect publication-selection and context-dependence. The reviewβs own acknowledgement of glioma contradiction is a sign of such context dependence.
Clinical-translation gap: The review states that BCYRN1-targeted therapies have not been tested clinically (at the time). This matters because biomarker diagnostic/prognostic association does not imply therapeutic tractability.
Evidence confidence (from the provided text only)
Higher confidence within this review text: directionality statements (e.g., βupregulated in tumorsβ and βpoor survival associationsβ) are described as recurring themes across cited studies, and sample size numbers/diagnostic metrics are explicitly listed in tables.
Lower confidence: mechanistic causality across all cancer types (miRNA axes and pathway interactions) is asserted but the review does not, within the provided text, provide comparative effect sizes, experimental controls, or convergence testing across laboratories.
6) Author review links (for the paperβs authors)
Explore deep dives via BGPT author-specific reviews.
Feedback:
Updated: March 25, 2026
BGPT Paper Review
Study Novelty
50%
The work is a narrative synthesis of already-studied BCYRN1/BC200 cancer literature and repeats common mechanistic themes (miRNA axes; major oncogenic pathways) rather than introducing a new experimental framework or quantitative meta-analytic approach.
Scientific Quality
60%
Within the provided text, the review is structured and includes tables with explicit sample sizes/diagnostic metrics and notes a specific contradictory example in glioma. However, as a narrative review it lacks a described systematic methodology, reproducible data pipeline, and quantitative synthesis; mechanistic claims are not validated with uniform standards across studies.
Study Generality
70%
By covering multiple cancer types and summarizing cross-cutting mechanistic themes, it has broad contextual utility for hypothesis generation, though the strength of generalization depends on how consistent underlying mechanisms truly are across contexts (the review itself notes exceptions).
Study Usefulness
70%
It usefully aggregates: (i) where BCYRN1 is reported upregulated, (ii) which phenotypes are reported in preclinical models, and (iii) sample-size/diagnostic metrics in select cohorts, while clearly stating translational gaps (no clinical BCYRN1-targeted therapy tested).
Study Reproducibility
40%
As a narrative review, reproducibility depends on locating and re-running all cited primary studies. The provided text does not include a systematic search protocol, data extraction worksheet, or deposited code/data to reproduce its tables/claims from the literature corpus.
Explanatory Depth
60%
It explains multiple proposed mechanistic routes at a high level (miRNA interactions and multiple signaling pathways) and gives example axes, but does not resolve causal hierarchy or quantify how much each mechanism contributes across cancer types.
Extract Table 3 and 4 values from the review text, structure them into tidy arrays, and generate publication-quality plots of sample sizes and diagnostic metrics for each cancer subtype.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
The strongman hypothesis that BCYRN1 is always oncogenic across all cancers is undermined by the reviewβs own contradictory glioma findings.
The hypothesis that βmiRNA spongeβ is the only relevant mechanism is too narrow given the reviewβs explicit references to multiple signaling pathways and alternative axes (e.g., CDK2/cyclin E2, STAT3 modulation, and direct protein-level effects described in its summaries).
Quick Explanation
Long Explanation
Top Data Sources
ExportMCP
Keep Exploring
Analysis Wizard
Hypothesis Graveyard
Potential Experiments
Discussion
Fuel Your Discoveries
Ask a Follow-Up
Key Insight
